
|Videos|April 10, 2017
Adjusting Dosing to Increase Efficacy of Cetuximab in Head and Neck Cancer
Author(s)Joseph Ciccolini, PhD
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5






































